vTv Therapeutics primarily focuses its clinical research and drug development pipeline on metabolic disorders and severe autoimmune conditions. Its flagship programs have historically evaluated oral therapies targeted at improving glycemic control in patients suffering from type 1 diabetes and type 2 diabetes, alongside exploring novel treatments for related immune-mediated inflammatory diseases.